TY - JOUR
T1 - Isolated +15 in bone marrow
T2 - Disease-associated or a benign finding?
AU - Goswami, Rashmi Shivani
AU - Liang, Cynthia S.
AU - Bueso-Ramos, Carlos E.
AU - Hu, Shimin
AU - Goswami, Maitrayee
AU - Yin, C. Cameron
AU - Lu, Gary
AU - Medeiros, L. Jeffrey
AU - Tang, Guilin
N1 - Publisher Copyright:
© 2014 Elsevier Ltd.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - It has been controversial if trisomy 15 (+15) as an isolated clonal cytogenetic abnormality in bone marrow (BM) is disease-associated or a benign finding. To answer this question, we retrospectively reviewed our cytogenetic archives and identified 31 patients with isolated +15. Four patients presented with acute myeloid leukemia (AML), +15 was the major clone (56-95% of interphases) in BM and the clonal size of +15 was correlated with blast burden and disease status. For the remaining 27 patients, +15 was a minor clone (3-24% of interphases) in BM. Eighteen patients had a history of cytotoxic therapies and developed +15 after a median latency interval of 34 months. Six patients had BM involvement by lymphoma or myeloma, and +15 was exclusively detected in myeloid and erythroid cells, not in lymphoma or myeloma cells. With a median follow-up of 28 months, none of these 27 patients had clinical or morphological evidence of myelodysplastic syndromes. We conclude that +15 can be associated with AML, but more often isolated +15 presents as a minor clone in BM, and may not be disease associated. Clinical follow-up rather than an immediate therapeutic intervention seems most appropriate for non-leukemic patients with isolated +15.
AB - It has been controversial if trisomy 15 (+15) as an isolated clonal cytogenetic abnormality in bone marrow (BM) is disease-associated or a benign finding. To answer this question, we retrospectively reviewed our cytogenetic archives and identified 31 patients with isolated +15. Four patients presented with acute myeloid leukemia (AML), +15 was the major clone (56-95% of interphases) in BM and the clonal size of +15 was correlated with blast burden and disease status. For the remaining 27 patients, +15 was a minor clone (3-24% of interphases) in BM. Eighteen patients had a history of cytotoxic therapies and developed +15 after a median latency interval of 34 months. Six patients had BM involvement by lymphoma or myeloma, and +15 was exclusively detected in myeloid and erythroid cells, not in lymphoma or myeloma cells. With a median follow-up of 28 months, none of these 27 patients had clinical or morphological evidence of myelodysplastic syndromes. We conclude that +15 can be associated with AML, but more often isolated +15 presents as a minor clone in BM, and may not be disease associated. Clinical follow-up rather than an immediate therapeutic intervention seems most appropriate for non-leukemic patients with isolated +15.
KW - AML
KW - Clinical significance
KW - Post cytotoxic therapy
KW - Trisomy 15
UR - http://www.scopus.com/inward/record.url?scp=84920388084&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920388084&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2014.11.005
DO - 10.1016/j.leukres.2014.11.005
M3 - Article
C2 - 25435027
AN - SCOPUS:84920388084
SN - 0145-2126
VL - 39
SP - 72
EP - 76
JO - Leukemia Research
JF - Leukemia Research
IS - 1
ER -